|
Ibtrozi (taletrectinib) is approved for ROS1-positive NSCLC, showing high efficacy in TRUST-I and TRUST-II trials. Treatment-naive patients had response rates of 90% and 85%, with significant duration of response in both trials. Previously treated patients showed response rates of 52% and 62%, with notable duration of response. The FDA expedited approval through priority review, breakthrough therapy, and orphan drug designations. Ibtrozi's serious side effects include liver issues, pneumonitis, QTc prolongation, and hyperuricemia; recommended dose is 600 mg daily. (责任编辑：) |